Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease

Frederick R. Singer, Thomas Clemens, Rachelle A. Eusebio, Pirow J. Bekker

Research output: Contribution to journalArticle

Abstract

Thirteen patients with severe Paget's disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg oral risedronate daily for 8 weeks. Patients were followed for 16 weeks without treatment. The change from baseline SAP was the primary end point. Those patients whose SAP levels did not reach the normal range were retreated with 30 mg for another 8 weeks. There was a mean percent decrease in SAP of 77% after the first course of risedronate treatment and 87% after the second course of treatment. All patients who completed the study had a decrease in SAP of at least 77% from the baseline. The urinary hydroxyproline/creatinine level was decreased by 64% and 79%, respectively, during the first and second treatment courses. There were transient asymptomatic decreases in serum calcium and phosphorus levels. The urinary calcium/creatinine ratio also decreased in these patients. Serum intact PTH and 1,25-dihydroxyvitamin D levels increased transiently during risedronate treatment. Oral risedronate was well tolerated by the patients. Only one patient discontinued treatment because of an adverse event (diarrhea) thought to be related to risedronate therapy.

Original languageEnglish (US)
Pages (from-to)1906-1910
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume83
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Alkaline Phosphatase
Serum
Creatinine
Patient treatment
Calcium
Therapeutics
Hydroxyproline
Osteitis Deformans
Phosphorus
Bone
Risedronate Sodium
Diarrhea
Reference Values

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. / Singer, Frederick R.; Clemens, Thomas; Eusebio, Rachelle A.; Bekker, Pirow J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 6, 1998, p. 1906-1910.

Research output: Contribution to journalArticle

Singer, Frederick R. ; Clemens, Thomas ; Eusebio, Rachelle A. ; Bekker, Pirow J. / Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. In: Journal of Clinical Endocrinology and Metabolism. 1998 ; Vol. 83, No. 6. pp. 1906-1910.
@article{3ae0fd35af0c4b47ab20ad7e12542532,
title = "Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease",
abstract = "Thirteen patients with severe Paget's disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg oral risedronate daily for 8 weeks. Patients were followed for 16 weeks without treatment. The change from baseline SAP was the primary end point. Those patients whose SAP levels did not reach the normal range were retreated with 30 mg for another 8 weeks. There was a mean percent decrease in SAP of 77{\%} after the first course of risedronate treatment and 87{\%} after the second course of treatment. All patients who completed the study had a decrease in SAP of at least 77{\%} from the baseline. The urinary hydroxyproline/creatinine level was decreased by 64{\%} and 79{\%}, respectively, during the first and second treatment courses. There were transient asymptomatic decreases in serum calcium and phosphorus levels. The urinary calcium/creatinine ratio also decreased in these patients. Serum intact PTH and 1,25-dihydroxyvitamin D levels increased transiently during risedronate treatment. Oral risedronate was well tolerated by the patients. Only one patient discontinued treatment because of an adverse event (diarrhea) thought to be related to risedronate therapy.",
author = "Singer, {Frederick R.} and Thomas Clemens and Eusebio, {Rachelle A.} and Bekker, {Pirow J.}",
year = "1998",
doi = "10.1210/jc.83.6.1906",
language = "English (US)",
volume = "83",
pages = "1906--1910",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease

AU - Singer, Frederick R.

AU - Clemens, Thomas

AU - Eusebio, Rachelle A.

AU - Bekker, Pirow J.

PY - 1998

Y1 - 1998

N2 - Thirteen patients with severe Paget's disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg oral risedronate daily for 8 weeks. Patients were followed for 16 weeks without treatment. The change from baseline SAP was the primary end point. Those patients whose SAP levels did not reach the normal range were retreated with 30 mg for another 8 weeks. There was a mean percent decrease in SAP of 77% after the first course of risedronate treatment and 87% after the second course of treatment. All patients who completed the study had a decrease in SAP of at least 77% from the baseline. The urinary hydroxyproline/creatinine level was decreased by 64% and 79%, respectively, during the first and second treatment courses. There were transient asymptomatic decreases in serum calcium and phosphorus levels. The urinary calcium/creatinine ratio also decreased in these patients. Serum intact PTH and 1,25-dihydroxyvitamin D levels increased transiently during risedronate treatment. Oral risedronate was well tolerated by the patients. Only one patient discontinued treatment because of an adverse event (diarrhea) thought to be related to risedronate therapy.

AB - Thirteen patients with severe Paget's disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg oral risedronate daily for 8 weeks. Patients were followed for 16 weeks without treatment. The change from baseline SAP was the primary end point. Those patients whose SAP levels did not reach the normal range were retreated with 30 mg for another 8 weeks. There was a mean percent decrease in SAP of 77% after the first course of risedronate treatment and 87% after the second course of treatment. All patients who completed the study had a decrease in SAP of at least 77% from the baseline. The urinary hydroxyproline/creatinine level was decreased by 64% and 79%, respectively, during the first and second treatment courses. There were transient asymptomatic decreases in serum calcium and phosphorus levels. The urinary calcium/creatinine ratio also decreased in these patients. Serum intact PTH and 1,25-dihydroxyvitamin D levels increased transiently during risedronate treatment. Oral risedronate was well tolerated by the patients. Only one patient discontinued treatment because of an adverse event (diarrhea) thought to be related to risedronate therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031762884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031762884&partnerID=8YFLogxK

U2 - 10.1210/jc.83.6.1906

DO - 10.1210/jc.83.6.1906

M3 - Article

C2 - 9626117

AN - SCOPUS:0031762884

VL - 83

SP - 1906

EP - 1910

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -